The firm continues rapid growth with the addition of industry-recognized experts on cybersecurity, data privacy, and IT risk management talent.

More than 100,000 infusion pumps were found susceptible to severe vulnerabilities that were disclosed roughly three years ago, according to researcher at Palo Alto Networks’ Unit 42.

read more

Business Combination Leverages Strength of Leading Providers of Revenue Cycle Management Services Healthcare Resource Group, Inc. Transaction Highlights: 2021 revenues and adjusted EBITDA of $33.8 million and $3.6 million, respectively 2022 expected revenues and adjusted EBITDA of $40.1 million and $5.2 million, respectively (pre-synergies) Synergies to provide an additional estimated $2.6 million margin improvement to […]

The post CPSI Announces the Acquisition of Healthcare Resource Group, Inc. appeared first on Fintech News.

TOKYO and KENILWORTH, N.J., Feb 25, 2022 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A., for radically unresectable or metastatic renal cell carcinoma (RCC). LENVIMA plus KEYTRUDA is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC. This marks the second approval of this combination in Japan; in December 2021, LENVIMA plus KEYTRUDA was approved for unresectable, advanced or recurrent endometrial carcinoma that progressed after chemotherapy. The approval is based on results from the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial, in which LENVIMA plus KEYTRUDA demonstrated statistically significant improvements versus sunitinib in the primary efficacy outcome measure of progression-free survival (PFS). Results showed LENVIMA plus KEYTRUDA (n=355) reduced the risk of disease progression or death by 61% (HR=0.39 [95% CI, 0.32-0.49]; p<0.0001), with a median PFS of 23.9 months versus 9.2 months for sunitinib (n=357).

"Nearly one in three cases of renal cell carcinoma are diagnosed at an advanced stage,(1) and patients are in need of new treatment options that may improve survival outcomes,(2)" said Dr. Gregory Lubiniecki, Vice President, Oncology Clinical Research, Merck & Co., Inc., Kenilworth,

N.J., U.S.A. Research Laboratories. "In the CLEAR/KEYNOTE-581 trial, KEYTRUDA plus LENVIMA reduced the risk of disease progression or death by 61% versus sunitinib, a current standard of care. We are encouraged that patients with certain types of advanced renal cell carcinoma may have the opportunity to benefit from this combination."

"Today's milestone for LENVIMA plus KEYTRUDA as a treatment for radically unresectable or metastatic renal cell carcinoma is particularly exciting as it marks the second approval for the combination in Japan," said Terushige Iike, President of Eisai Japan, Senior Vice President, Eisai. "We are thrilled to be able to provide Japanese patients with a new treatment option, illustrating our shared commitment with Merck & Co., Inc., Kenilworth, N.J., U.S.A. to develop therapies with the aim of addressing the unmet needs of those living with difficult-to-treat cancers. We would like to thank the patients, families and healthcare providers who made this approval possible."

The Japanese package inserts for LENVIMA and KEYTRUDA note that in the CLEAR/KEYNOTE-581 trial, adverse reactions were observed in 341 (96.9%) of 352 patients (including 42 of 42 Japanese patients) in the safety analysis set. The most common adverse reactions included diarrhea in 192 patients (54.5%), hypertension in 184 patients (52.3%), hypothyroidism in 150 patients (42.6%), decreased appetite in 123 patients (34.9%), fatigue in 113 patients (32.1%), stomatitis in 113 patients (32.1%), palmar-plantar erythrodysesthesia syndrome in 99 patients (28.1%), proteinuria in 97 patients (27.6%), nausea in 94 patients (26.7%), dysphonia in 87 patients (24.7%), rash in 77 patients (21.9%), and asthenia in 71 patients (20.2%).

Renal cell carcinoma is the most common type of kidney cancer worldwide; about nine out of 10 kidney cancer diagnoses are RCC.(3) In Japan, there were more than 25,000 new cases of kidney cancer diagnosed and more than 8,000 deaths from the disease in 2020.(4) Approximately 30% of patients with RCC will have metastatic disease at diagnosis.(5) Survival is highly dependent on the stage at diagnosis, and with a five-year survival rate of 14% for patients diagnosed with metastatic disease, the prognosis for these patients is poor.(6)

Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. continue to study the LENVIMA plus KEYTRUDA combination across several types of cancer with more than 20 clinical trials.

For more information, visit https://www.eisai.com/news/2022/pdf/enews202214pdf.pdf.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA.

The healthtech sector has risen consistently over the past years, but the COVID-19 pandemic undeniably accelerated that growth, acting as a catalyst for investment in an already burgeoning sector. In

The post 6 Healthtech Startups From Singapore to Watch in 2022 appeared first on Fintech Singapore.

The partnership enables participation in North Carolina’s health information exchange (HIE) for thousands of SimplePractice customer practices serving clients using insurance LOS ANGELES–(BUSINESS WIRE)–SimplePractice, an EngageSmart (NYSE: ESMT) solution and industry-leading platform simplifying the health and wellness experience, announced that it has partnered with Smartlink Health Solutions, a pioneer in bidirectional health data exchange via […]

The post SimplePractice Partners with Smartlink Health Solutions to Enable Whole Patient Care in North Carolina appeared first on Fintech News.

Radicle Science launches several blinded placebo-controlled clinical trials on rare cannabinoids with 10,000 participants in the first half of 2022 on the heels of completing 25 large-scale CBD studies in 2021. SAN DIEGO–(BUSINESS WIRE)–#cannabinoids—Radicle Science, a transformative healthtech B-corp validating health and wellness products for the first time, will launch history’s first large-scale, blinded, placebo-controlled […]

The post Radicle Science Makes History Again With First Large-Scale Clinical Trials on Rare Cannabinoids, Including THCV, CBN, CBG, and CBC appeared first on Fintech News.

Bass, Berry & Sims’ 10th annual Healthcare Fraud & Abuse Review 2021 provides analysis of healthcare fraud enforcement actions, False Claims Act developments and scrutiny of cybersecurity and...

(PRWeb February 10, 2022)

Read the full story at https://www.prweb.com/releases/covid_19_relief_funding_for_healthcare_organizations_will_be_under_the_governments_microscope_in_2022_and_beyond/prweb18488126.htm

Saudi hospital implements digital credentialing using blockchain. The solution was developed by the hospital’s Blockchain Lab. Doctors will be able ...

Read More...

Firm Named No.1 Best in KLAS for Security & Privacy Consulting Services

(PRWeb February 08, 2022)

Read the full story at https://www.prweb.com/releases/impact_advisors_receives_24th_best_in_klas_distinction_in_15_years_more_than_doubling_other_service_providers/prweb18485411.htm

MOBILE, Ala.–(BUSINESS WIRE)–$CPSI–CPSI (NASDAQ: CPSI), a community healthcare solutions company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2021, on Tuesday, February 15, 2022, after the market closes. The Company will host a conference call at 4:30 p.m. Eastern Time that same day. The live […]

The post CPSI to Webcast Its Fourth Quarter and Year-End 2021 Conference Call appeared first on Fintech News.

- The acquisition bolsters HMI Group's offering of complete one-stop healthcare services and capabilities to patients in Singapore and the region - The partnership strengthens HMI Group and EEC's market position in Southeast Asia, and positions HMI Group for continued growth, synergies, and expansion

Singapore, Jan 24, 2022 - (ACN Newswire) - Health Management International Pte Ltd (HMI Group), a growing regional private healthcare provider with presence in Singapore, Malaysia and Indonesia, has acquired a majority stake in Eagle Eye Centre Pte Ltd (EEC), the largest private ophthalmology chain in Singapore. "With our investment, we will partner with EEC and work closely with the EEC doctors to grow the business locally and in the region," said Ms Chin Wei Jia, Group Chief Executive Officer of HMI Group. "This is a significant step in expanding HMI Group's portfolio into the specialist medical services as we strive to provide one-stop healthcare services both within and outside of hospitals." Founded in 2006, EEC started out as a one-stop specialist eye care facility, and was amongst the first to offer comprehensive ophthalmic care with services in all eye subspecialties under one roof. Today, EEC operates a chain of seven ophthalmology centres in Singapore together with 17 resident eye specialists. EEC offers a full suite of ophthalmic subspecialties including Cornea and Anterior Segment; Ocular Immunology and Uveitis; Cataract; Refractive Surgery; Glaucoma; Medical and surgical Retina; Neuro-Ophthalmology; Paediatrics and Strabismus; and Oculoplastic. Delivering convenience and value The EEC acquisition complements the Group's Singapore strategy, which focuses on providing quality and patient-centred healthcare services outside of hospitals that are convenient and delivers value. Furthermore, it will accelerate HMI Group's journey to capture the growing global trend of day surgery procedures, especially in developed markets, as medical skills and technology continue to advance. In Singapore, about 50% of surgical procedures can be performed in day surgery setting. "With HMI Group's expertise and reach in the region, we will continue to enhance access to high quality healthcare services for the people we serve. Through our investments in non-hospital settings, we are better prepared to deliver care in the future of health. HMI Group has a unique opportunity to use the momentum for change created by the COVID-19 crisis to accelerate the transformation of outpatient care," Ms Chin said. "We will also have the collective experience and extensive track record of Dr Julian Theng, Dr Lim Wee Kiak, and EEC's team of highly skilled sub-specialised ophthalmologists, to provide comprehensive optometric and ophthalmic care. We look forward to supporting EEC's growth ambitions and are excited to welcome the team into the HMI family." Expanding into specialist eye centres also enhances HMI Group's portfolio of primary care clinics and ambulatory care centres in Singapore. EEC recently built operating theatres and day procedure suites in King Albert Park and Royal Square Novena to perform common day surgery procedures such as Cataract and LASIK procedures outside of a hospital setting. The EEC acquisition is HMI Group's second in 2021. In September, HMI Group acquired a majority stake in OneCare Medical, a chain of 25 primary care clinics in Singapore. Through organic growth and the 2 new acquisitions, HMI Group's EBITDA has grown about 70% since HMI Group de-listed in December 2019 in a management buy-out together with EQT, a global investment firm, to now become one of the largest privately held healthcare providers in Southeast Asia. "Joining HMI Group presents a strategic opportunity for us to extend our ophthalmic services not just locally but regionally. We are thrilled to have found a purpose-driven, like-minded partner in HMI Group. With a common heart in a patient-centric approach to healthcare, while trusting us to continue leading in the ophthalmic medical management of EEC, our collective aim is to make a positive impact in our communities as we grow together," said Dr Julian Theng, Group Chairman and Medical Director of EEC. "We are optimistic about the further development of our business while tapping on synergies across the Group to better serve our patients." About Health Management International Pte Ltd Health Management International Pte Ltd ("HMI" or the "Group") is a growing regional private healthcare provider with presence in Singapore, Malaysia and Indonesia. The Group owns and operates two tertiary hospitals in Malaysia. In Singapore, the Group owns and operates a healthcare training centre, a primary care clinic chain with 25 locations, and Singapore's first private one-stop ambulatory care centre. The Group also has a network of representative offices in Indonesia, Malaysia and Singapore. Established in 1994, Mahkota Medical Centre ("Mahkota") is HMI Group's flagship hospital located in the heart of Malacca and is the first JCI-accredited hospital in Malacca. The 340-bed hospital is the largest private tertiary hospital in South Malaysia, and is the first and only hospital in Malacca to offer nuclear medicine and kidney transplant services. Mahkota sees close to 100,000 international patients per year and was named the "Malaysia Medical Tourism Hospital of the Year" by Frost & Sullivan in 2015 and 2016. The Group's second hospital, Regency Specialist Hospital ("Regency") was launched in 2009 and is one of the fastest growing private tertiary hospitals in Malaysia located in the state of Johor. The 218-bed Regency is the only private hospital in Malaysia with a 24-hour Emergency & Trauma Centre, providing round the clock specialist attention and medical care to both local and international patients. Regency is in the midst of building a major hospital extension block to increase capacity up to 500 beds. The Group holds a majority stake in StarMed Specialist Centre ("StarMed"), a one-stop day-surgery and multidisciplinary medical centre that offers quality clinical services at competitive private sector prices. The Group also holds a majority stake in OneCare Medical, a fast-growing primary care clinic chain with 25 clinics across Singapore. HMI Group's healthcare training centre, the HMI Institute of Health Sciences, is the Group's Social Enterprise arm and a SkillsFuture Singapore accredited Continuing Education and Training Centre for the healthcare support sector. For more information, please refer to www.hmi.com.sg. About Eagle Eye Centre Pte Ltd Established in 2006, Eagle Eye Centre Pte Ltd ("EEC") is the largest private ophthalmology chain in Singapore. EEC operates a chain of 7 ophthalmology centres in Singapore together with 17 resident eye specialists. EEC offers a full suite of ophthalmic subspecialties including Cornea & Anterior Segment, Ocular Immunology & Uveitis, Cataract, Refractive Surgery, Glaucoma, Retina, Neuro-Ophthalmology, Paediatrics & Strabismus and Oculoplastics. EEC is committed to deliver quality eye care treatment at affordable prices that can best serve the mass community and constantly invests in technology to keep up with its pace. EEC was recognised as the Ophthalmology Service Provider of the Year by Global Health Awards for the past 5 consecutive years. For more information, please refer to www.eagleeyecentre.com.sg. Contact: Chi-an Chang, Director, Financial PR [email protected]

Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comHealth Management International Pte Ltd (HMI Group), a growing regional private healthcare provider with presence in Singapore, Malaysia and Indonesia, has acquired a majority stake in Eagle Eye Centre Pte Ltd (EEC), the largest private ophthalmology chain in Singapore.